trial · primary record
Biospecimen Collection
Acute Myeloid Leukemia
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 5 |
| Primary completion | 2026-11-05 |
| Primary endpoint | Recommended Safe Phase 2 Dose (RP2D) of Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax (Phase Ib) |
| Registry ID | NCT04817241 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:36.599Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04817241
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Biospecimen Collection · compound